EMA Approves Antimicrobial Resistance Drug
The agency recommends the approval of Zavicefta to treat infections caused by resistant bacteria.
On April 29, 2016, the European Medicines Agency (EMA) recommended granting marketing authorization for Zavicefta (ceftazidime/avibactam) for treating patients with infections caused by resistant bacteria. The recommendation by the EMA Committee for Medicinal Products for Human Use (CHMP) will be sent to the European Commission for a decision about whether or not to approve the drug for use across the European Union (EU).
The approval comes as part of a global effort to tackle antimicrobial resistance. EMA estimates that 25,000 patients in the EU die from treatment-resistant bacteria yearly. EMA has been monitoring and analyzing data on antimicrobials to create policy and promote responsible use. A 2013 EMA guidance allows for a flexible approach to developing new antibiotics to fight these resistant pathogens.
Zavicefta treats adults with intra-abdominal infections, urinary tract infections, and pneumonia acquired in a hospital setting. According to EMA, Zavicefta is a fixed combination a new beta-lactamase inhibitor, avibactam, and a third-generation cephalosporins antibiotic, ceftazidime, already approved for use in the EU. Avibactam inhibits beta-lactamases, which are enzymes involved in antibiotic resistance, and restores the activity of ceftazidime against ceftazidime-resistant pathogens. Avibactam also works against many of the carbapenem-resistant Enterobacteriaceae, which is currently an unmet medical need with few treatment options.
It is also used to treat infections caused by Gram-negative bacteria, which also has limited treatment options. EMA states, “the efficacy of Zavicefta against certain Gram-negative bacteria has been demonstrated in the clinical trials that underpin the approval of the indications of intra-abdominal and urinary tract infections, and hospital-acquired pneumonia. CHMP considered that it is beneficial to make Zavicefta available for patients with infections caused by Gram-negative bacteria, when they have few or no therapeutic options to fight the disease, and recommended to include treatment of these patients in the product information on the basis of a limited set of data.”
Source: EMA
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
